ESC 365 - Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF).

ESC Professional Premium Access

Safety of the oral Factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF).

Session: Recent features from The Lancet

Topic: Other

Speaker: Professor J. Piccini (Durham, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Jonathan Piccini

Duke University Medical Center, Durham (United States of America)

5 presentations

1 follower

3 more presentations in this session

A preview of The Lancet Commission on sudden cardiac death.

Speaker: Professor E. Marijon (Paris, FR)

Reduction of dietary sodium to less than 100mmol in heart failure (SODIUM-HF).

Speaker: Professor J. Ezekowitz (Edmonton, CA)

Long-term prevention of cardiovascular disease with a Mediterranean diet (CORDIOPREV).

Speaker: Doctor J. Delgado-Lista (Cordoba, ES)

Access the full session

Recent features from The Lancet

Speakers: Professor J. Piccini, Professor E. Marijon, Professor J. Ezekowitz, Doctor J. Delgado-Lista

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources